Woodline Partners LP Has $93.59 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Woodline Partners LP raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 359,088 shares of the medical research company’s stock after buying an additional 51,138 shares during the period. Amgen comprises 0.6% of Woodline Partners LP’s portfolio, making the stock its 19th biggest position. Woodline Partners LP’s holdings in Amgen were worth $93,593,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Vident Advisory LLC increased its holdings in shares of Amgen by 173.0% in the fourth quarter. Vident Advisory LLC now owns 19,331 shares of the medical research company’s stock valued at $5,039,000 after purchasing an additional 12,250 shares in the last quarter. Visionary Wealth Advisors increased its holdings in shares of Amgen by 3.3% in the fourth quarter. Visionary Wealth Advisors now owns 26,895 shares of the medical research company’s stock valued at $7,010,000 after purchasing an additional 865 shares in the last quarter. Vivaldi Capital Management LP increased its holdings in shares of Amgen by 3,192.3% in the fourth quarter. Vivaldi Capital Management LP now owns 61,730 shares of the medical research company’s stock valued at $17,453,000 after purchasing an additional 59,855 shares in the last quarter. Waters Parkerson & CO. LLC increased its holdings in shares of Amgen by 17.3% in the fourth quarter. Waters Parkerson & CO. LLC now owns 4,581 shares of the medical research company’s stock valued at $1,194,000 after purchasing an additional 677 shares in the last quarter. Finally, St. Clair Advisors LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $730,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 1.3%

AMGN opened at $275.85 on Tuesday. The stock has a market capitalization of $148.33 billion, a P/E ratio of 36.54, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The firm’s fifty day simple moving average is $290.27 and its 200 day simple moving average is $287.56. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. The business had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.96 EPS. As a group, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.45%. Amgen’s dividend payout ratio is currently 86.86%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on AMGN. UBS Group reissued a “neutral” rating and issued a $315.00 price target (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Piper Sandler lowered their price target on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a report on Friday. Morgan Stanley reissued an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Erste Group Bank lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Finally, StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Sunday. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $310.18.

Insider Activity at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.76% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.